<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478097</url>
  </required_header>
  <id_info>
    <org_study_id>A70_09BE2005</org_study_id>
    <nct_id>NCT04478097</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open, Single-dose, 3 Period Partial Replicated Crossover-design Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of CKD-333 or Co-administration of CKD-330 and D086 in Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, open, single-dose, 3 period partial replicated crossover-design
      study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy
      volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of fifty-one (51), following treatments are administered dosing in each
      period and wash-out period is a minimum of 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 14, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-330, D086, CKD-333</measure>
    <time_frame>[Time Frame: Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours]</time_frame>
    <description>Area under the CKD-330/D086/CKD-333 concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-330, D086, CKD-333</measure>
    <time_frame>[Time Frame: Pre-dose (0 hour), post-dose 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours]</time_frame>
    <description>The maximum CKD-330/D086/CKD-333 concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Reference-Reference-Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference-Test-Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test-Reference-Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 Tab. and D086 Tab.</intervention_name>
    <description>1T</description>
    <arm_group_label>Reference-Reference-Test</arm_group_label>
    <arm_group_label>Reference-Test-Reference</arm_group_label>
    <arm_group_label>Test-Reference-Reference</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-333 Tab.</intervention_name>
    <description>1T</description>
    <arm_group_label>Reference-Reference-Test</arm_group_label>
    <arm_group_label>Reference-Test-Reference</arm_group_label>
    <arm_group_label>Test-Reference-Reference</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults over the age of 19 years and under the age of 55 years at the time of
             screening

          2. Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) &lt; 30.5kg/m2 and men's total body
             weight ≥ 55 kg, women's total body weight ≥ 45 kg

             * BMI = Weight(kg)/ Height(m)2

          3. Individuals without congenital/chronic diseases and without abnormal symptoms or
             diagnosis based on a medical examination within the last 3 years

          4. Individuals who were deemed to be appropriate as study subjects following laboratory
             tests (hematology, blood chemistry, urinalysis, viral/bacterial, etc.) and vital
             signs, ECG etc. performed at screening

          5. Individuals who signed an informed consent form and decided to participate in the
             study after being fully informed of the study prior to participation

          6. Individuals who agreed proper contraception during the study and did consent to not
             donation of sperm 1 month after the last dose of study drug infusion

          7. Individuals with the ability and willingness to participate the entire study period

        Exclusion Criteria:

          1. Individuals with a medical evidence or a history of clinically significant
             hepatobiliary, renal, neurologic, respiratory, digestive, endocrine, blood-oncology,
             urinary, cardiovascular, musculoskeletal or psychiatric

          2. Individuals with a medical history of gastrointestinal disease (e.g., Crohn's disease
             and ulcer) or gastrectomy (excluding simple appendectomy or herniotomy) that may
             affect drug absorption

          3. Individuals with the following results at screening test:

               -  ALT or AST &gt; 2x the upper limit of the normal range

               -  Creatinine &gt; upper limit of the normal range or eGFR with MDRD &lt;60 ml/min/1.73 m2

               -  ECG Result, QTc &gt; 450msec

               -  CPK &gt; UNL(upper normal limit) x 3.0

               -  K &gt; 5.5mEq/l

               -  Hct &lt; lower limit of the normal range

          4. A history of regular alcohol consumption exceeding 21 units/week within the 3 months(1
             unit = 10 g = 12.5 ml) prior to screening or individuals who cannot quit drinking from
             48hr prior to the first dose to end of last blooding (1 drink (250 mL) of beer (5%) =
             10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12
             g)

          5. Individuals who smoked more than 20 cigarettes per day within 6 months prior to
             screening or cannot quit smoking during hospitalization period

          6. Individuals who had been administered investigational product(s) of other clinical
             study or bioequivalence study within the 6 months prior to the first dose of this
             study

          7. Following vital signs results at screening

               -  Sitting systolic blood pressure ≥ 140 mmHg or &lt; 90 mmHg

               -  sitting diastolic blood pressure ≥90 mmHg or &lt;60 mmHg

          8. Individuals with a medical history of significant drug abuse within one year prior to
             the screening or positive for abuse drug in urine test results at screening

          9. Individuals taking medication known to significantly induce or inhibit drug
             metabolizing enzymes within 30days before the first administration of clinical trial
             drug

         10. Individuals who had taken prescription or nonprescription drugs within the 10 days
             prior to the first dose of investigational product(s)

         11. Individuals who donated whole blood within the 2 months, or blood components within 1
             month prior to the first dose of the investigational product(s)

         12. Individuals with hypersensitivity to investigational products or the investigational
             products ingredients

         13. Patients or conditions deemed to be at risk for using investigational products

               -  Patient with hyperkalemia

               -  Patients with hepatopathy

               -  Patients with hereditary angioedema, ACE inhibitors or angiotensin 2 receptor
                  antagonists who have a history of angioedema

               -  Primary hyperaldosteronism

               -  Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic
                  obstructive cardiomyopathy

               -  Patients with ischemic heart disease, ischemic cardiovascular disease,
                  cerebrovascular disease

               -  Patients with Intravascular volume depletion

               -  Patients with diabetes or kidney failure

               -  Patients with renal artery stenosis

               -  Patients with muscle disease

               -  Patients with Hypothyroidism

               -  Patients with a history of muscle toxicity when using statins or fibrates

               -  Patients who have recently had a kidney transplant

               -  Patients with history of shock

         14. Individuals with hereditary diseases of galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption etc.

         15. Individuals who drunk grapefruit juice or caffeine more than 5 cup per day within 3
             months prior to screening or cannot quit drinking during clinical trials period

         16. Individuals who cannot eat standard meal in institution

         17. Women who are pregnant or may be pregnant

         18. Individuals who were deemed to be inappropriate to participate in the study by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jang Hee Hong</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 17, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

